Aerovate Therapeutics, Inc.
NASDAQ:AVTE
2.72 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 0 | 0.136 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 0.028 | 0.028 | 0.028 | 0.025 | 0.022 | 0.021 | 0.02 | 0.02 | 0.017 | 0.011 | 0.008 | 0.003 | 0.002 | 0.002 | 0 | 0 | 0 | 0 |
Gross Profit
| -0.028 | -0.028 | 0.108 | -0.025 | -0.022 | -0.021 | -0.02 | -0.02 | -0.017 | -0.011 | -0.008 | -0.003 | -0.002 | -0.002 | 0 | 0 | 0 | 0 |
Gross Profit Ratio
| 0 | 0 | 0.794 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 21.248 | 20.08 | 17.813 | 16.884 | 16.034 | 13.488 | 12.221 | 10.783 | 8.363 | 7.255 | 5.046 | 3.418 | 4.327 | 2.196 | 3.297 | 1.966 | 1.471 | 1.206 |
General & Administrative Expenses
| 4.917 | 4.538 | 4.253 | 4.484 | 4.302 | 4.151 | 3.631 | 3.369 | 3.852 | 3.764 | 3.222 | 2.782 | 1.447 | 0.584 | 0.366 | 0.277 | 0.154 | 0.152 |
Selling & Marketing Expenses
| -0.028 | -0.028 | -0.028 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 4.889 | 4.51 | 4.225 | 4.484 | 4.302 | 4.151 | 3.631 | 3.369 | 3.852 | 3.764 | 3.222 | 2.782 | 1.447 | 0.584 | 0.366 | 0.277 | 0.154 | 0.152 |
Other Expenses
| -0.006 | -0.003 | 0.001 | 0.001 | -0.001 | -0.001 | -0.077 | 0.004 | -0.006 | 0 | 0.001 | 0 | -0.003 | -0.001 | -0.003 | -0.064 | -0.54 | -0.04 |
Operating Expenses
| 26.137 | 24.59 | 22.038 | 21.368 | 20.336 | 17.639 | 15.852 | 14.152 | 12.215 | 11.019 | 8.268 | 6.2 | 5.774 | 2.78 | 3.663 | 2.243 | 1.625 | 1.358 |
Operating Income
| -26.165 | -24.618 | -22.066 | -21.368 | -20.336 | -17.639 | -15.852 | -14.152 | -12.215 | -11.019 | -8.268 | -6.2 | -5.774 | -2.78 | -3.663 | -2.243 | -1.625 | -1.358 |
Operating Income Ratio
| 0 | 0 | -162.25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 1.39 | 1.432 | 1.709 | 1.805 | -0.001 | 1.119 | 0.855 | 0.564 | 0.224 | 0.109 | 0.001 | 0.016 | -0.003 | -0.001 | -0.003 | -0.064 | -0.54 | -0.04 |
Income Before Tax
| -24.775 | -23.186 | -20.357 | -19.563 | -19.025 | -16.52 | -14.997 | -13.588 | -11.991 | -10.91 | -8.22 | -6.184 | -5.775 | -2.781 | -3.666 | -2.307 | -2.202 | -1.436 |
Income Before Tax Ratio
| 0 | 0 | -149.684 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| 0 | -0.015 | 0.056 | -0.025 | -1.312 | -1.119 | 0.025 | -0.564 | -0.224 | -0.109 | 0.003 | 0 | -0.002 | -0.001 | -0.647 | -2.243 | -1.588 | 0.038 |
Net Income
| -24.775 | -23.186 | -20.413 | -19.563 | -19.025 | -15.401 | -15.022 | -13.024 | -11.767 | -10.801 | -8.223 | -6.184 | -5.775 | -2.781 | -3.666 | -2.307 | -2.202 | -1.436 |
Net Income Ratio
| 0 | 0 | -150.096 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS
| -0.86 | -0.83 | -0.74 | -0.71 | -0.76 | -0.62 | -0.61 | -0.53 | -0.48 | -0.44 | -0.34 | -0.26 | -23.76 | -0.13 | -15.08 | -9.49 | -9.06 | -0.32 |
EPS Diluted
| -0.86 | -0.83 | -0.74 | -0.71 | -0.76 | -0.62 | -0.61 | -0.53 | -0.48 | -0.44 | -0.34 | -0.26 | -23.76 | -0.13 | -15.08 | -9.49 | -9.06 | -0.32 |
EBITDA
| -26.137 | -24.59 | -22.038 | -21.368 | -20.314 | -17.618 | -15.832 | -14.132 | -12.198 | -11.008 | -8.26 | -6.197 | -5.772 | -2.779 | -4.309 | -2.243 | -1.625 | -1.398 |
EBITDA Ratio
| 0 | 0 | -162.044 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |